Fetal damage during anticoagulant therapy for antepartum thromboembolic disease by Lodhia, Kanchan L.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
MD Theses Special Collections 
5-1-1969 
Fetal damage during anticoagulant therapy for antepartum 
thromboembolic disease 
Kanchan L. Lodhia 
University of Nebraska Medical Center 
This manuscript is historical in nature and may not reflect current medical research and 
practice. Search PubMed for current research. 
Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses 
 Part of the Medical Education Commons 
Recommended Citation 
Lodhia, Kanchan L., "Fetal damage during anticoagulant therapy for antepartum thromboembolic disease" 
(1969). MD Theses. 102. 
https://digitalcommons.unmc.edu/mdtheses/102 
This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It 
has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For 
more information, please contact digitalcommons@unmc.edu. 
FETAL DAMAGE DURING ANTICOAGULANT THERAPY 
FOR ANTEPARTUM THROMBOEMBOLIC DISEASE 
by 
Kanchan L. Lodhia 
A THESIS 
Presented to the Faculty of 
The College of Medicine in the University of Nebraska 
In Partial Fulfillment of Requirements 
For the Degree of Doctor of Medicine 
Under the Supervision of Robert H. Messer, M.D. 
Omaha, Nebraska 
February 3, 1969 
TABLE OF CONTENTS 
Introduction 
Extent and Incidence 
Pathophysiology 














FETAL DAMAGE DUHING ANTICOAGULANT THEHAPY 
FOR ANTEPARTUM THROMBOElfffiOLIC DISEASE 
Introduction 
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Although thromboembolic phenomenon occurs 
relatively rarely in pregnancy, possible adverse effect 
on the fetus during therapy makes it a subject of sig-
nificant concern in antenatal care. In this paper the 
recent literature is reviewed for the prevalence of the 
disease, its pathophysiology, therapy, and the risk to 
the fetus. Four new cases are presented, and the dangers 
of anticoagulant therapy are discussed. 
Extent and Incidence 
Thromboembolic disease may manifest as phlebo-
thrombosis without primary associated inflammation of 
the vessel wall. More commonly there is mural pathology 
associated with the attached thrombus wherefore the term 
thrombophlebitis is appropriately descriptive. The in-
volvement of a more vital organ, the lungs, when a dis-
lodged thrombus is carried away by the blood stream causes 
a high incidence of sudden deaths and makes pulmonary em-
bolism a dreaded third member of the triad in thromboem-
bolic disease. 
Aaro, Johnson, and Juergens l found the most 
common type of venous thrombosis associated with preg-
nancy to be thrombophlebitis of superficial, usually varicose, 
veins of the lower extremity. Deep venous thromboses 
were found in the veins of the lower extremity as well 
as in the pelvis. However, pelvic thrombophlebitis is 
stated to be seen most frequently with postpartum in-
fection and sepsis. The authors found pulmonary em-
bolism in two out of nine cases of antepartum deep 
thrombophlebitis. Husni, Pena, and Lenhart 5 reported 
four cases of pulmonary embolism among 20 cases of 
superficial and deep thrombophlebitis during pregnancy. 
They found that phlebitis occurred predominantly in the 
last trimester, and very rarely during the first tri-
mester of pregnancy. For some unexplained reason Aaro 
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et all found antepartum thrombophlebitis to have a marked 
predilection for the left lower extremity as compared 
to an even distribution between the left and the right 
legs after pregnancy is terminated. 
Ullery6 reported an incidence of antepartum 
thrombophlebitis to be 0.018 percent in his series in 
1954. Aaro et all found 87 cases of thrombophlebitis 
during 25,082 pregnancies, an incidence of 0.15 percent. 
Villasanta8 reported an incidence of 0.027 percent in 
43,790 pregnant women. Husni et a1 5 reported an inci-
dence of 0.085 percent in 23,485 pregnancies. 
Pathophysiology 
Since Virchow's triad of conditions predisposing 
to thrombosis were proposed over a century ago, viz. 
(1) blood stasis, (2) vessel injury, and (3) hyperco-
agulability of the blood, very little has been added 
to further illuminate the mechanism and biochemistry 
of thrombus formation. 7 The precise interrelation of 
the various factors involved in the in vivo clotting 
of blood have not been fully worked up. Villasanta8 
states that the proposed theories fail to explain the 
relatively low overall incidence of thromboembolic 
disease in pregnancy in spite of the conditions in 
gestation that enhance intravascular clotting of the 
blood: varicose veins, increased intra-abdominal 
pressure on the iliac veins with resultant venous 
stasis in the lower extremities; arteriovenous shunt 
in the placenta with consequent increased venous in-
competency in the lower extremities; anemia; obesity; 
and increased blood fibrinogen level. Furthermore, 
Beller2 observes that in the postpartum period the 
concentration of blood coagulation factors declines 
from the markedly high levels during pregnancy to 
almost normal values by the third postpartum day in 
most instances, yet statistically the incidence of pul-
monary embolism is highest at this time. In spite of 
our lack of thorough knowledge in this field, signifi-
cant progress has been made in therapy and prophylaxis 
during the past few decades. 
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Therapy and Risks 
Avoidance of prolonged bed rest, elevation of 
the lower extremities, proper hydration, and use of elastic 
stockings or elastic wraps on the legs promote good venous 
return and comprise accepted practice in prophylaxis for 
thrombophlebitis during pregnancy in the more susceptible 
patient. Surgical therapy, exemplified by venous ligation, 
vein stripping, and embolectomy is uncommon during preg-
nancy. Anticoagulant treatment is today the mainstay in 
thromboembolic disease during gestation. 
Before anticoagulants came into use, the disease 
often progressed to pulmonary embolism and death. Villa-
santa's9 review of the literature up till 1964 revealed a 
mortality of 12.8 percent among 163 pregnant females with 
thrombophlebitis who received no anticoagulants. Among 
134 antepartum patients treated with anticoagulants, the 
mortality was 0.7 percent. Heparin, bishydroxycoumarin 
(Dicumarol), or a combination of the two were used. More 
recently dextran has been found promising. 3 ,5,8 Heparin 
prolongs the clotting time by acting as an antithrombin 
and antithromboplastin. The coumarin derivatives, known 
also as the oral anticoagulants, act indirectly by de-
pressing formation of blood clotting factors II, VII, IX, 
and X. Dextran prevents the agglutination of red cells, 
decreases the whole blood viscosity, and produces a mo-
lecular coating over the intima of the blood vessel. 
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Anticoagulant therapy entails definite risks 
both to the mother as well as the fetus. Among contra-
indications to anticoagulant use are thrombocytopenic 
purpura, open wounds or ulcerations, impaired hepatic or 
renal function, hypertension, subacute bacterial endocar-
ditis, peptic ulcers, colitis, and esophageal varices. 
Hemorrhage is the major complication of anticoagulant 
therapy. Vi11asanta9 nevertheless found in the literature 
very few cases of complications to the mother following 
anticoagulant treatment. 
Possible danger to the human fetus during ante-
partum anticoagulant therapy could have been predicted 
even before the coumarin derivatives were isolated. It 
was after the incrimination of sweet clover eaten by the 
pregnant cow as the cause of hemorrhagic disease in new-
born calves that investigations by Link and his associ-
ates (as narrated by Vigran7) led to the discovery of the 
coumarin compounds. Indeed nature had provided the first 
animal experiment for safety of the oral anticoagulants 
in pregnancy. Reports of successful use of coumarin drugs 
as well as adverse effects to the fetus without harm to 
the mother began to appear after the first use of the 
coumarin drugs in antepartum thrombophlebitis in 1945. 
Cases of fetal death with maceration of the fetus 4 were 
described in association with anticoagulant treatment. 
Nevertheless, Ullery6, in 1954, concluded that the risk 
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to the mother as well as the fetus was minimal when pro-
thrombin time was maintained between 18 and 23 seconds 
(20 to 30 percent of normal). Villasanta8 found 17 
reported cases of thrombophlebitis treated with heparin 
as the sole anticoagulant with no ill effect on the fetus. 
In contrast, in 89 published cases treated with coumarin 
derivatives, he found 14 cases of fetal death in utero 
and four additional cases of fatal hemorrhagic lesions 
in the newborn, giving a mortality of 20 percent. In 
another report Villasanta9 found in the literature two 
cases of surviving children with congenital anomalies 
related to coagulation defect. The fatal cases included 
a stillborn infant with hemorrhage of the thymus as well 
as other organs; a neonatal death with tentorial tears; 
another stillborn with multiple hemorrhages; a few cases 
of intrauterine death with severe maceration masking pos-
sible evidence of hemorrhage; and a case of abortion. 
Villasanta found no particular coumarin deriva-
tive to be incriminated more than any other. Similarly., 
the total doses given, as well as the duration of treat-
ment were found to be insignificant. Extreme prolongation 
of the prothrombin time is thought not to be responsible 
for the fetal hemorrhages since one mother with prolonga-
tion of the prothrombin time to 97 seconds delivered a 
normal baby whereas death from hemorrhages were reported 
in cases with maintenance of prothrombin time at recommended 
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values. 
Four cases of adverse effect to the fetus during 
anticoagulant therapy, including two from the University 
of Nebraska Hospital, are now presented. 
Case Reports 
Case No.1 
The patient was a 35 year old para 3-0-1-3 whose 
last menstrual period was on December 15, 1956, and whose 
expected date of confinement was September 22, 1957. This 
patient had severe rheumatic heart disease and had been on 
anticoagulants for some years, primarily on bishydroxycou-
marin (Dicumarol). Because of fibrillation, she was also 
on digitalis. The general trend had been to maintain a 
prothrombin time around 30 to 40 percent of normal, seldom 
ranging below 25 percent. The obstetrician's office 
records contain the following laboratory values: 
Date Prothrombin time 
March 11, 1967 37 percent 
March 26, 1967 40 percent 
April 23, 1967 21 percent 
June 25, 1967 15 percent 
Between the office visit on June 25 and the next 
one a week later, fetal heart tones and fetal movements 
had disappeared. The patient delivered spontaneously by 
breech presentation five weeks prematurely. The fetus was 
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estimated to have been dead in utero for three weeks. Un-
fortunately, a postmortem examination was not performed. 
Records do not show evidence of gross hemorrhagic lesions. 
Case No.2 
This 21 year old Negro female para 2-1-0-2 with 
a history of the last menstrual period on September 8, 
1963, and an expected term date of June 15, 1964 was ad-
mitted to the hospital on October 14, 1963, for thrombo-
phlebitis of the right lower extremity. She had a past 
history of recurrent thromboplhebitis and grand mal epi-
lepsy. She was said to have had either plication or 
ligation of the inferior vena cava early in 1963. Records 
show the following drug doses and laboratory values: 
Date Sodium Warfarin Prothrombin Control 
(Coumadin) Dose Time 
October 15 40 mgm 18 sec 13 sec 
October 16 20 mgm 22 sec 12 sec 
October 17 10 mgm 29 sec 12 sec 
October 19 5 mgm 
October 20 5 mgm 38 sec 12 sec 
October 21 5 mgm 
October 22 5 mgm 35 sec 14 sec 
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Additionally, 100 mgm of heparin TID was given 
on October 15, 16, and 17. She also received phenylbutazone 
during hospitalization. Diphenylhydantoin (Dilantin) and 
primidone (Mysoline) prescribed during her hospital stay 
were continued upon discharge in October following satis-
factory recovery. Anticoagulants were discontinued after 
October 22. 
The patient was readmitted on November 24 with 
recurrence of the thrombophlebitis in the right lower ex-
tremity. She was given phenylbutazone, and anticoagulants 
were given according to the following schedule with the 
laboratory values as shown: 
Date Sodium Warfarin Prothrombin Control 
(Coumadin) Dose Time 
November 4 40 mgm 
November 5 10 mgm 14 sec 12 sec 
November 6 5 mgm 22 sec 12 sec 
November 7 5 mgm 27 sec 12 sec 
November 8 5 mgm 28 sec 13 sec 
November 9 26 sec 12 sec 
November 10 7.5 mgm 
November 11 7.5 mgm 22 sec 12 sec 
November 12 10 mgm 22 sec 12 sec 
November 13 15 mgm 15 sec 13 sec 
November 14 14 sec 12 sec 
November 15 30 mgm 
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Date Sodium Warfarin Prothrombin Control 
(Coumadin) Dose Time 
November 16 5 mgm 30 sec 13 sec 
November 17 5 mgm 30 sec 13 sec 
November 18 5 mgm 29 sec 14 
November 19 17.5 mgm 25 sec 13 sec 
November 20 24 sec 13 sec 
November 21 5 mgm 31 sec 13 sec 
November 22 34 sec 13 sec 
November 23 22 sec 13 seC 
November 24 7.5 mgm 18 sec 13 sec 
November 25 
November 26 15 mgm 
November 27 15 mgm 17 sec 13 sec 
November 28 15 mgm 21 sec 12 sec 
November 29 10 mgm 31 sec 14 sec 
November 30 7.5 mgm 44 sec 14 sec 
December 1 7.5 mgm 33 sec 13 sec 
December 2 7.5 mgm 37 sec 13 sec 
December 3 10 mgm 
The patient was dismissed from the hospital on 
December 3 and arrangements were made for a visiting nurse 
to supervise an alternating warfarin dose of 7.5 mgm and 
10 mgm per day_ Blood was obtained on an outpatient basis 
for the following prothrombin time values: 
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Date Prothrombin Time Control 
December 3 29 sec 13 sec 
December 9 35 sec 14 sec 
December 16 19 sec 13 sec 
December 23 46 sec 14 sec 
December 30 53 sec 14 sec 
On December 23 the drug dose was increased to 
10 mgm daily following the preceding week's low prothrom-
bin time. On December 30 warfarin was stopped when the 
prothrombin time for the previous week was seen to be 46 
seconds. She received 5 mgm of the drug on January 1, 
and 7.5 mgm on January 2. 
On the morning of January 3 she was admitted 
in active labor with vaginal bleeding. Fifteen mgm of 
phytonadione (Aquamephyton) was administered after the 
prothrombin time was found to be 24 seconds. A 5 lb. 1 oz. 
stillborn female was delivered. No record of an autopsy 
or description of any obvious hemorrhage are found. 
Case No.3 
This 38 year old white female para 3-0-1-3 with 
a history of the last menstrual period on June 20, 1965, 
and estimated date of term of March 27, 1966 was hospitalized 
at another hospital from October 13 until October 19 for 
right axillary vein thrombophlebitis. She had a long term 
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history of bleeding tendencies. Records show the following: 
Date Sodium Warfarin Prothrombin Control 
(Coumadin) Dose Time 
October 13 12.5 sec 12 sec 
October 14 50 mgm 
October 15 15 mgm 22 sec 11 sec 
October 16 7.5 mgm 25 sec 12 sec 
October 17 10 mgm 
October 18 10 mgm 30 sec 12 sec 
October 19 7.5 mgm 
A total of 350 mgm of heparin was given on the 
13th and a clotting time of 40 minutes is recorded. From 
the 14th until the 17th of October, she received 200 mgm 
of heparin daily. Clotting time was 27 minutes on October 
14. She also received phenylbutazone (Butazolidin) while in 
the hospital. She was dismissed on October 19 on 7.5 mgm 
of warfarin daily. During an office visit on October 25 
her prothrombin time was 31 seconds with a control of 14 
seconds. 
On November 10 the patient was admitted again, 
for acute and chronic abdominal pain. Prothrombin time was 
found to be 18 seconds with a control of 11 seconds. Micro-
hematuria was seen, and a possibility of internal hemorrhage 
prompted cessation of anticoagulant administration at this 
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time. She was dismissed after a few days with no further 
anticoagulant therapy. 
The patient was seen for the first time at the 
University Hospital for a prenatal checkup on December 10. 
During subsequent visits she gave a history of spotting on 
December 14, and bleeding hemorrhoids on December 20. 
She was admitted to the University Hospital on 
March 14, 1966, for chronic back pain, obesity, mild hyper-
tension, fatigue from overwork, and for observation for 
possible future recurrence of axillary vein thrombosis 
during the remainder of her pregnancy. Following a rela-
tively uneventful course she delivered an 8 lb. 14 oz. 
female infant with hydrocephalus after oxytocin induction. 
At approximately one month of age, the child underwent a 
craniotomy at which time an old hematoma, estimated to be 
formed prenatally, was found. The child is institution-
alized at the present time. 
Case No.4 
This 22 year old white female nullipara was ad-
mitted to the hospital on February 20, 1967, with a diagnosis 
of a missed abortion. Her estimated date of confinement was 
July 1, 1967. She had a past history of pulmonary embolism 
treated with vena cava plication and ligation of the ovarian 
veins. On a previous admission, she was started on sodium 
warfarin (Coumadin) prophylaxis when it was learned that 
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she was pregnant. The following drug doses and laboratory 
values are available: 
Date Sodium Warfarin Prothrombin Control 
(Coumadin) Dose Time 
December 8 13 sec 13 sec 
December 9 40 mgm 
December 10 7.5 mgm 16 sec 14 sec 
December 11 10 mgm 14 sec 13 sec 
December 13 10 mgm 32 sec 13 sec 
December 14 10 mgm 
December 15 15 mgm 18 sec 13 sec 
December 16 10 mgm 18 sec 13 sec 
From December 16 until December 21 the patient 
received 10 mgm of the drug daily. From December 22 until 
January 25 she took 7.5 mgm daily. From January 26 until 
delivery after hospitalization on February 20, 5 mgm 
and 7.5 mgm were prescribed on alternate days. Prothrombin 
time after December 16 are shown below: 
Date Prothrombin Time Control 
December 22 37 sec 13 sec 
December 29 32 sec 13 sec 
January 5 24 sec 13 sec 
January 26 32 sec 13 sec 
February 9 22 sec 13 sec 
February 23 19 sec 13 sec 
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A few days after admission she went spontaneously 
into labor and delivered a dead male fetus. Other data 
are not available on the fetus. 
Comments 
The four cases presented add to the mounting 
evidence against the use of the coumarin drugs during preg-
nancy. However, controlled studies are lacking on the 
subject apparently due to the relative rarity of the 
disease during pregnancy. In the cases found in the li-
terature as well as those presented here, unequivocal 
evidence of hemorrhage is lacking in a large percentage 
of the fetuses lost. It is therefore not surprising that 
proponents of continued utilization of oral anticoagulants 
in pregnancy as well as those convinced otherwise are both 
found at present. 
There is little doubt that heparin is safe for 
the fetus when given to the mother with careful maintenance 
of clotting time within a recommended range. Its safety 
lies in its high molecular weight of around 20,000 that 
probably prohibits passage through the placenta. On the 
other hand a molecular weight of approximately 1,000 appar-
ently allows the coumarin drugs to pass through the pla-
cental barrier and into the fetus. The fortuitous phe-
nomenon that results are not disastrous to a larger per-
centage of fetuses is explained by Be11er2 to be due to a 
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compensation mechanism for the inadequate production of 
coagulation factors in the fetal liver. Despite the 
deficiency of blood coagulation factors, the bleeding 
and clotting time in the newborn as well as the fetus are 
found to be shorter than in the adult. Hemorrhagic 
complications in the fetus are thought to arise when 
these unknown compensatory mechanisms are functioning 
improperly. 
Studies on the treatment of acute thrombo-
phlebitis with dextran have aroused enthusiasm among 
investigators. Cox, Flotte, and Buxton3 reported in 1965 
on the treatment of thrombophlebitis with dextran of 
average molecular weight of 75,000 as well as with dex-
tran 40,000. They found that as the time interval be-
tween onset of symptoms and the initiation of therapy 
passes 48 hours the chances of objective improvement are 
much reduced. When used within 48 hours of onset of symp-
toms it was found to be an effective treatment. Husni 
et a1 5 reported in 1967 on 20 cases of antepartum deep 
thrombophlebitis treated either conservatively, with 
anticoagulants, or with dextran. They found a remarkably 
good response to dextran with no untoward results to the 
fetus. 
Unfortunately, dextran cannot completely replace 
the coumarin drugs in pregnancy in spite of its apparent 
advantages of relative ease of administration and the lack 
of a need for specific laboratory control. Nevertheless, an 
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attempt to use dextran instead of the coumarin compounds 
in acute antepartum thrombophlebitis merits serious con-
sideration. 
The low cost of the oral anticoagulants plus 
the ease of administration which make them suitable for 
outpatient therapy undoubtedly are the major factors that 
account for their popularity both in antepartum and in 
general use. Clearly, research is indicated to discover 
new anticoagulants which would combine the above advant-
ages with characteristics that guarantee safety to the 
fetus. In the meantime perhaps an extra effort should be 
made by the clinician to replace the coumarins with the 
other available therapeutic agents, heparin and dextran, 
where feasible. 
Summary 
Thromboembolic phenomenon characterized by throm-
bophlebitis, phlebothrombosis, and pulmonary embolism is 
rare during pregnancy. Pathophysiology of the disease is 
poorly understood. 
Anticoagulant therapy markedly reduces the asso-
ciated high mortality. The coumarin drugs are incriminated 
in adverse effect on the fetus during antepartum thrombo-
phlebitis in the four cases presented, adding mounting 
evidence against their use in pregnancy. Until new and 
safer drugs are available, heparin and dextran should be 
utilized where possible. 
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